Fig. 3.

A 45-year-old female patient with a brain metastasis secondary to a BRAF-mutated malignant melanoma treated with dabrafenib and trametinib. Comparison of contrast-enhanced MR and FET PET images at baseline (left column) and follow-up 8 weeks later (right column). At follow-up, a clear decrease of the tumor/brain ratios (−35%) is observed, whereas the MRI shows no significant change of both the contrast enhancement and FLAIR signal defined as stable disease according to RANO criteria for brain metastases. The metabolic response was associated with an overall survival of 9 months after treatment initiation.